NCT04101357: A reported trial by Biontech SE
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04101357 |
|---|---|
| Title | Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 19, 2020 |
| Completion date | Jan. 19, 2024 |
| Required reporting date | Jan. 18, 2025, midnight |
| Actual reporting date | Jan. 16, 2025 |
| Date last checked at ClinicalTrials.gov | July 3, 2026 |
| Days late | None |